Related references
Note: Only part of the references are listed.Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
TRANSLATIONAL MEDICINE Cancer lessons from mice to humans
David Tuveson et al.
NATURE (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy
Anil Bagri et al.
CLINICAL CANCER RESEARCH (2010)
Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis
Christopher W. Chiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Mallika Singh et al.
NATURE BIOTECHNOLOGY (2010)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Activity of sunitinib in patients with advanced neuroendocrine tumors
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular imaging in drug development
Juergen K. Willmann et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas
Hiroki Sakamoto et al.
ULTRASOUND IN MEDICINE AND BIOLOGY (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Stromal biology of pancreatic cancer
Gerald C. Chu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Maximizing mouse cancer models
Kristopher K. Frese et al.
NATURE REVIEWS CANCER (2007)
Visualization of nascent tumor angiogenesis in lung and liver metastasis by differential dual-color fluorescence imaging in nestin-linked-GFP mice
Yasuyuki Amoh et al.
CLINICAL & EXPERIMENTAL METASTASIS (2006)
Mouse Modeling in oncologic preclinical and translational research
Brett S. Carver et al.
CLINICAL CANCER RESEARCH (2006)
Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse
N Bardeesy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Model organisms - The mighty mouse: genetically engineered mouse models in cancer drug development
Norman E. Sharpless et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model
K Yokoi et al.
CANCER RESEARCH (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Differential diagnosis of pancreatic tumors using ultrasound contrast imaging
A Sofuni et al.
JOURNAL OF GASTROENTEROLOGY (2005)
Trp53R172H and KraSG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
SR Hingorani et al.
CANCER CELL (2005)
A multitargeted, metronomic, and maximum-tolerated dose chemo-switch regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
K Pietras et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate
M Furuhashi et al.
CANCER RESEARCH (2004)
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
KP Olive et al.
CELL (2004)
Molecular regulation of pancreatic stellate cell function
Robert Jaster
MOLECULAR CANCER (2004)
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
AJ Aguirre et al.
GENES & DEVELOPMENT (2003)
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
SR Hingorani et al.
CANCER CELL (2003)
Regulation of pancreatic stellate cell function in vitro:: biological and molecular effects of all-trans retinoic acid
R Jaster et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice
G Bergers et al.
COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY (2002)
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis
M Inoue et al.
CANCER CELL (2002)
Share Paper
